The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa heart study

Atherosclerosis

Volumn 123, Issue 1-2, 1996, Pages 33-42

  Srinivasan, Sathanur R ^a   Ehnholm, Christian ^b   Wattigney, Wendy A ^a   Weihang, Bao ^a   Berenson, Gerald S ^a  

^a Tulane Center for Cardiovascular Health   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

ApoE polymorphism; Cardiovascular risk factors; Children; Insulin; Obesity

Indexed keywords

APOLIPOPROTEIN E; ENDOGENOUS COMPOUND; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029882647     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05762-5     Document Type: Article

References (51)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34.
2. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622.
3. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 1977;269:604.
4. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Human Genet 1981;33:11.
5. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1.
6. Utermann G, Pruin N, Steinmetz A. Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin Genet 1979;15:63.
7. Ehnholm C, Lukka M, Kuusi T, et al. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res 1986;27:227.
8. Boerwinkle E, Visvikis S, Welsh D, et al. The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet 1987;27:567.
9. Weisgraber SH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982;257:2518.
10. Kesäniemi AY, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987;80:578.
11. Havel RJ, Chao Y, Windler EE, et al. Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of dysbetalipoproteinemia. Proc Natl Acad Sci USA 1980;77:4349.
12. Brenninkmeijer BJ, Stuyt PH, Demacker PN, et al. Catabolism of chylomicron remnant in normolipidemic subjects in relation to the apolipoprotein E phenotype. J Lipid Res 1987;28:361.
13. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 1987;80:1571.
14. Cumming AM, Robertson FW. Polymorphism at the apoprotein E locus in relation to risk of coronary disease. Clin Genet 1984;25:310.
15. Kuusi T, Nieminen MS, Ehnholm C, et al. Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E4 in angiographically verified coronary patients. Arteriosclerosis 1989;9:237.
16. Utermann G, Hardewig A, Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet 1984;65:237.
17. Menzel HJ, Kladetzky RG, Assman G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 1993;101:9.
18. Eto M, Watanabe K, Makino J. Increased frequencies of apolipoprotein E2 and E4 alleles in patients with ischemic heart disease. Clin Genet 1989;36:183.
19. Ukkola O, Kervinen K, Salmela PI, Dickhoff K, Laakso M, Kesäniemi YA. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 1993;101:9.
20. Hixson JE and the Pathobiologic Determinants of Atherosclerosis in Youth (PDAY) Research Group. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arterioscler Thromb 1991;11:1237.
21. Eichner JE, Kuller LH, Orchard TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and morbidity from coronary artery disease. Am J Cardiol 1993;71:160.
22. Neiminen MS, Mattila KJ, Alto-Setälä, et al. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb 1992;12:58.
23. Stengård JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265.
24. Lehtimäki T, Moilanen T, Viikari J, et al. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res 1990;31:487.
25. Srinivasan SR, Ehnholm C, Wattigney W, Berenson GS. Apolipoprotein E polymorphism and its association with serum lipoprotein concentrations in black versus white children: The Bogalusa Heart Study. Metabolism 1993;42:381.
26. Xu C-F, Talmud PJ, Angelico F, et al. Apolipoprotein E polymorphism and plasma lipid, lipoprotein, and apolipoprotein levels in Italian children. Genet Epidemiol 1991;8:389.
27. Williams DP, Going SB, Lohman TG, et al. Body fatness and risk for elevated blood pressure, total cholesterol, serum lipoprotein ratios in children and adolescents. Am J Public Health 1992;82:358.
28. Lipid Research Clinics Program: Manual of Laboratory Operations Vol. 1. National Institute of Health, DHEW Publication No. (NIH) 75-628, Bethesda, MD, 1974.
29. Srinivasan SR, Berenson GS. Serum lipoproteins in children and methods for study. In: Lewis LA (ed.), CRC Handbook of Electrophoresis, Vol. 3, Lipoprotein Methodology and Human Studies. Boca Raton, FL: CRC Press, 1983:185-204.
30. Havekes L, de Knijeff P, Beisiegel U, et al. A rapid micro-method for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987;28:455.
31. SAS User's Guide: Statistics, Version 6, SAS Institute, Cary, NC, 1989.
32. Fleiss JL. Statistical methods for rates and proportions. 2nd edn. New York: John Wiley and Sons, 1980.
33. Hallman DM, Boerwinkle E, Saha W, et al. The apolipoprotein polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Human Genet 1991;49:338.
34. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol use to predict coronary heart disease. Circulation 1983;67:730.
35. Pouliot M-C, Després J-P, Moorjani S, et al. Apolipoprotein E polymorphism alters the association between body fatness and plasma lipoproteins in women. J Lipid Res 1990;31:1023.
36. Després J-P, Verdon M-F, Moorjani S, et al. Apolipoprotein E polymorphism modified relation of hyperinsulinemia to hypertriglyceridemia. Diabetes 1993;42:1474.
37. Uusitupa M, Sarkkinen E, Kervinen K, Kesäniemi YA. Apolipoprotein E phenotype and blood pressure. Lancet 1994;343:57.
38. Kissebah AH, Freedman DS, Peiris, AW. Health risk of obesity. Med Clin North Am 1989;73:111.
39. Després J-P, Allard C, Tremblay A, et al. Evidence for a regional component of body fatness in the association with serum lipids in men and women. Metabolism 1985;34:967.
40. Freedman DS, Srinivasan SR, Harsha DW, et al. Relation of body fat patterning to lipid and lipoprotein concentrations in children and adolescents. The Bogalusa Heart Study. Am J Clin Nutr 1989;50:930.
41. Berenson GS, Voors AW, Webber LS, et al. Racial differences of parameters associated with blood pressure levels in children - The Bogalusa Heart Study. Metabolism 1979;28:1218.
42. Mitchell BD, Haffner SM, Hazuda HP, Valdez R, Stern MP. The relation between serum insulin levels and 8-year changes in lipid, lipoprotein, and blood pressure levels. Am J Epidemiol 1992;136:12.
43. Ferrannini E, Buzzigoli G, Banadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350.
44. Olefsky JM, Kolterman OG, Scarlett JA. Insulin action and resistance in obesity and non-insulin-dependent type II diabetes mellitus. Am J Physiol 243 (1982) E15.
45. Bao W, Srinivasan SR, Wattigney WA, Berenson GS. Persistence of multiple cardiovascular risk clustering related to Syndrome X from childhood to young adulthood. The Bogalusa Heart Study. Arch Intern Med 1994;154:1842.
46. Khoury P, Morrison JA, Kelly K, et al. Clustering and interrelationships of coronary heart disease risk factors in school children, ages 6-19. Am J Epidemiol 1980;112:524.
47. Criqui MH, Barrett-Connor E, Holdbrook MJ, et al. Clustering of cardiovascular disease risk factors. Prev Med 1980;9:525.
48. Kannel WB. The role of cholesterol in coronary atherogenesis. Med Clin North Am 1974;58:363.
49. Reaven RM. Role of insulin resistance in human disease. Banting Lecture 1988. Diabetes 1988;37:1595.
50. William RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension: evidence from 58 Utah families for a syndrome present in approximately 15% of patients with essential hypertension. J Am Med Assoc 1988;259:3579.
51. Tiret L, de Knijff P, Menzel H-J, Ehnholm C, Nicarrd V, Havekes LM, for the EARS Group. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. Arterioscler Thromb 1994;14:1617.